The mission of the UCSF-GIVI CFAR is to promote multidisciplinary research at the intersection of the basic, clinical and behavioral-epidemiological sciences with the goal of ending the global HIV epidemic. To fulfill its mission, CFAR collaborates with UCSF's Center for AIDS Prevention Studies (CAPS) to coordinate a multi-pronged program that includes: 1) providing scientific leadership and direction through a proactive planning process that identifies the most important challenges emerging at the leading edge of HIV research;2) assembling research teams across different disciplines and sites to address all dimensions of these identified challenges;3) maintaining an outstanding set of scientific cores that extends the scientific reach of Center investigators;4) ensuring a highly skilled, ethnically diverse, and thoughtful next generation of HIV investigators by providing a strong mentoring and pilot grants program unique at UCSF;5) directing CFAR's research and capacity building programs to international sites where the epidemic is hitting the hardest;6) engaging the communities we serve through a set of novel alliances involving Project Inform, the Forum for Collaborative HIV Research, and UCSF's Science and Health Education Partnership and 7) ensuring our programs are closely aligned with the NIH's AIDS programs, OAR's strategic plan for HIV/AIDS, and the President's National Strategy for HIV/AIDS. CFAR brings value by creafing and sustaining a true community of HIV/AIDS science. CFAR seeks transparency, discipline and inclusiveness in all of its operations and programs. CFAR is proud of its accomplishments in the last four years including publication of 1,172 papers, the mentoring of 44 early career investigators, the award of $4.1 million in CFAR grants and supplements to 85 scientists, the success of CFAR investigators in winning $135 million dollars in peer-reviewed, HIV related funding, and the planning and organization of the first Sub-Saharan Africa CFAR Conference that featured the work of African scientists from 13 countries and will help to build effective South-South collaborations. However, much work remains to be done. CFAR looks forward to helping stimulate progress on multiple scientific fronts including HIV and Aging, HIV eradication, increasing access to proven biomedical approaches to HIV prevention including chemoprophylaxis and reducing community viral load, and addressing disparities in HIV care and treatment within resource-limited communities in the Bay Area and abroad.

Public Health Relevance

The UCSF-GIVI CFAR is dedicated to promoting multidisciplinary research to accelerate progress in answering the important questions emerging in HIV/AIDS biology, treatment, and preven2ion. This approach has led to breakthrough discoveries advancing patient care and providing new approaches for curbing HIV infection in the United States and at international sites. CFAR is also committed to identifying and supporting the next generation of HIV investigators who are critical for truly ending the HIV epidemic.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-22
Application #
8485499
Study Section
Special Emphasis Panel (ZAI1-RRS-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2017-08-31
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
22
Fiscal Year
2013
Total Cost
$6,257,700
Indirect Cost
$1,196,854
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chammartin, Frédérique; Zürcher, Kathrin; Keiser, Olivia et al. (2018) Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis. Clin Infect Dis 67:1643-1652
Pulugulla, Sree H; Packard, Thomas A; Galloway, Nicole L K et al. (2018) Distinct mechanisms regulate IL1B gene transcription in lymphoid CD4 T cells and monocytes. Cytokine 111:373-381
Mohamed, Tamer M A; Ang, Yen-Sin; Radzinsky, Ethan et al. (2018) Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration. Cell 173:104-116.e12
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Vardi, Noam; Chaturvedi, Sonali; Weinberger, Leor S (2018) Feedback-mediated signal conversion promotes viral fitness. Proc Natl Acad Sci U S A 115:E8803-E8810
Carrico, Adam W; Flentje, Annesa; Kober, Kord et al. (2018) Recent stimulant use and leukocyte gene expression in methamphetamine users with treated HIV infection. Brain Behav Immun 71:108-115
Tymejczyk, Olga; Brazier, Ellen; Yiannoutsos, Constantin et al. (2018) HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Med 15:e1002534
Sauceda, John A; Lisha, Nadra E; Neilands, Torsten B et al. (2018) Cognitive-affective depressive symptoms and substance use among Latino and non-Latino White patients in HIV care: an analysis of the CFAR network of integrated clinical systems cohort. J Behav Med :
Carrico, Adam W; Cherenack, Emily M; Roach, Margaret E et al. (2018) Substance-associated elevations in monocyte activation among methamphetamine users with treated HIV infection. AIDS 32:767-771
AIDS-defining Cancer Project Working Group of IeDEA, COHERE in EuroCoord (2018) Non-Hodgkin lymphoma risk in adults living with HIV across five continents. AIDS 32:2777-2786

Showing the most recent 10 out of 1541 publications